Is SNN a good stock to buy? We came across a bullish thesis on Smith & Nephew plc on r/ValueInvesting by Senior_Tadpole_3913. In this article, we will summarize the bulls’ thesis on SNN. Smith & Nephew plc’s share was trading at $29.61 as of June 23rd. SNN’s trailing and forward P/E were 20.52 and 13.26 respectively according to Yahoo Finance.
Kotin/Shutterstock.com
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. SNN appears to offer an attractive value opportunity within the medical technology sector, combining a reasonable valuation with improving operational performance and multiple catalysts for shareholder returns.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite trading well below its 2021 levels, the company currently changes hands at roughly 13x forward earnings, around 15x free cash flow, and offers a free cash flow yield approaching 7%, metrics that appear undemanding relative to the quality and resilience of its orthopedic, sports medicine, and wound care franchises.
The investment case is supported by a meaningful increase in free cash flow from approximately £400 million to £635 million over the past several years, alongside improving margins and a significant reduction in leverage from 3.2x to 1.7x EBITDA, strengthening the balance sheet and increasing financial flexibility. Shareholders are also benefiting from a combination of a dividend yield of roughly 2.6% and a £400 million-plus share repurchase program, resulting in a substantial level of capital being returned.
Management’s RISE strategy provides an additional source of potential upside, targeting 6–7% annual revenue growth and a return on invested capital of 12–13% by 2028. If the company executes successfully against these goals, the current valuation could prove overly conservative and allow for a meaningful rerating of the shares. The recent increase in ownership by activist investor Cevian to more than 12% further strengthens the bullish thesis by creating additional pressure to improve performance and unlock value.
While concerns remain regarding operating margins that trail many medtech peers, lower returns on capital, competitive pressure from Chinese manufacturers, and an estimated $60 million tariff impact in 2026, these issues appear increasingly reflected in the valuation. As profitability improves and strategic targets are met, Smith & Nephew has the potential to deliver both earnings growth and multiple expansion, creating an attractive risk-reward profile for long-term investors.
Previously, we covered a bullish thesis on Stryker Corporation (SYK) by The Antifragile Investor in January 2025, which highlighted its MedTech leadership, robotic surgery innovation, and acquisition-driven growth. SYK’s stock price has depreciated by approximately 14.12% since our coverage. Senior_Tadpole_3913 shares a similar view but emphasizes on Smith & Nephew’s undervaluation, improving cash flow, shareholder returns, and potential rerating through its RISE strategy.
Smith & Nephew plc is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held SNN at the end of the first quarter which was 14 in the previous quarter. While we acknowledge the risk and potential of SNN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
